Bosutinib (SKI-606) Licensed by Pfizer

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrZTWM2OD1yLkC4NlMyKCEQvF2=MmLiV2FPT0WU
SW756MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LCWGlEPTB;MD6xOFAzPCBizszNMYfTRW5ITVJ?
CTV-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEX2XpBKSzVyPUCuNVY{QThiIN88US=>MWTTRW5ITVJ?
HSC-4Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7PTWM2OD1yLkG3NVU5KCEQvF2=M{jnVHNCVkeHUh?=
LAMA-84MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHWd3ZKUUN3ME2wMlI5PjZ2IDFOwG0>M4fON3NCVkeHUh?=
KU812MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\k[|M3UUN3ME2wMlM1ODZ6IDFOwG0>MljuV2FPT0WU
HCC1806NHXvOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jWWWlEPTB;MD6zOVIyPiBizszNMUnTRW5ITVJ?
DOKNX7yeoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTBwM{e3PFYhKM7:TR?=NXfRe29GW0GQR1XS
NCI-H209MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYroT5BjUUN3ME2wMlQxQDB6IDFOwG0>MVTTRW5ITVJ?
EoL-1-cellM2HWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TENmlEPTB;MD60NVU4PiBizszNMWnTRW5ITVJ?
H9MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwNEO0OlQhKM7:TR?=NV7QWY12W0GQR1XS
EM-2NEjFXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jWcWlEPTB;MD60N|g6KCEQvF2=MnX4V2FPT0WU
NCI-H292MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEG3fIxKSzVyPUCuOFQyODhiIN88US=>MlzzV2FPT0WU
697NEO2NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHBVXoyUUN3ME2wMlQ2PjN|IDFOwG0>M{nTcXNCVkeHUh?=
BHT-101M17hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTBwNE[1PUAh|ryPM1XE[3NCVkeHUh?=
BE-13NYLMb|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDTfIxKSzVyPUCuOFg2PzJiIN88US=>MVjTRW5ITVJ?
RS4-11M2LNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwNEi1PFQhKM7:TR?=M2XrXnNCVkeHUh?=
IGROV-1NV3pfY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13QZWlEPTB;MD60PFc6PyBizszNMl7iV2FPT0WU
KE-37M1yzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1H0fWlEPTB;MD60PVUxQSBizszNMlvEV2FPT0WU
BV-173NW\E[GZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwNUC3PVIhKM7:TR?=M1;5cnNCVkeHUh?=
MEG-01NUjlUFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjVTWM2OD1yLkWxNlE1KCEQvF2=Mln2V2FPT0WU
LB2241-RCCMkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:2cmFKSzVyPUCuOVM4OThiIN88US=>M{n4UXNCVkeHUh?=
ACHNNXWyW4g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHwTWM2OD1yLkW0NFY6KCEQvF2=NUi0VpI1W0GQR1XS
CTB-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz4[2lKSzVyPUCuOVQ5OiBizszNMUXTRW5ITVJ?
HT-1080M2W5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rtfmlEPTB;MD61OVM1QSBizszNMWTTRW5ITVJ?
CHL-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwNUW0OlUhKM7:TR?=Mn2yV2FPT0WU
EW-3M{XmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\DVmlEPTB;MD61OVk{PSBizszNM4PSfXNCVkeHUh?=
ES1M3rEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjwTWM2OD1yLk[3OFk5KCEQvF2=M2PDfHNCVkeHUh?=
KASUMI-1Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojlTWM2OD1yLkeyN|MhKM7:TR?=MVvTRW5ITVJ?
SW13NGHSNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwN{O3PVghKM7:TR?=NXL1XW5LW0GQR1XS
A3-KAWMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\rR3VKSzVyPUCuO|kzODhiIN88US=>NYmxW|JKW0GQR1XS
LB771-HNCNVfXR3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDCTWM2OD1yLkizNVA1KCEQvF2=MUjTRW5ITVJ?
OC-314NUT4R4pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\EbmlEPTB;MD64Olk3PSBizszNNVL6OphjW0GQR1XS
MLMAMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorkTWM2OD1yLkmwOlc2KCEQvF2=MV3TRW5ITVJ?
KARPAS-45MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjJ[WxKSzVyPUCuPVI1PjZiIN88US=>M1\1TXNCVkeHUh?=
CAL-27NUnxPY8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPLPZkzUUN3ME2wMlkzQTB4IDFOwG0>NETwNFJUSU6JRWK=
SK-NEP-1NEX3cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHe5SFNKSzVyPUCuPVczPDhiIN88US=>NFf4dI5USU6JRWK=
COR-L105NWXIfpV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fQdmlEPTB;MT6wNFM6PCBizszNMXLTRW5ITVJ?
TI-73M2rnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTFwMEG2OUAh|ryPMnjFV2FPT0WU
JVM-3MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Xzd2lEPTB;MT6wOVAyPyBizszNMVXTRW5ITVJ?
HAL-01MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETTdZRKSzVyPUGuNFg5OSBizszNNF\KeYhUSU6JRWK=
QIMR-WILNF;uelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTFwMEmwOVghKM7:TR?=NFnJPJNUSU6JRWK=
HSC-3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3wb2N4UUN3ME2xMlEyPzh|IDFOwG0>M4X1UHNCVkeHUh?=
KY821MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFwMUOzOVEhKM7:TR?=NX7iNWdLW0GQR1XS
5637NEnIdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\DTWM2OD1zLkGzPFA{KCEQvF2=NYHk[FNxW0GQR1XS
CAL-33M1PieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfD[oxKSzVyPUGuNVk{ODJiIN88US=>M4DpWXNCVkeHUh?=
ES4NWKzbIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrWSm1KSzVyPUGuNlA4QSBizszNNWPv[3JsW0GQR1XS
BHYNF;xbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfZN4hKSzVyPUGuNlI5QTJiIN88US=>MVXTRW5ITVJ?
LB1047-RCCMkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTFwMkO3PFUhKM7:TR?=MnXLV2FPT0WU
H4MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T5d2lEPTB;MT6yOFI2PSBizszNMXHTRW5ITVJ?
RPMI-8866M3jSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTFwMk[xNFYhKM7:TR?=MnPLV2FPT0WU
HO-1-N-1MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrx[YdkUUN3ME2xMlI3OzZ7IDFOwG0>MXfTRW5ITVJ?
BB30-HNCM2rHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v3SGlEPTB;MT6yPFcyPCBizszNM3nrc3NCVkeHUh?=
PC-14Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PjNGlEPTB;MT6yPVIxPSBizszNM2XuPHNCVkeHUh?=
NUGC-3NYrHSnBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTFwMkmzOVYhKM7:TR?=NITnXGxUSU6JRWK=
A4-FukMnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7GU|dKSzVyPUGuN|A4ODRiIN88US=>MljYV2FPT0WU
MHH-NB-11MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfIVVdKSzVyPUGuN|E{QDNiIN88US=>NIjRd3lUSU6JRWK=
KOSC-2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH4TWM2OD1zLkOxO|c2KCEQvF2=NICzXVlUSU6JRWK=
A498NV7iXWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFwNECxNVMhKM7:TR?=M2Tyc3NCVkeHUh?=
KG-1NVvXcGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXLU3Q3UUN3ME2xMlQyOjd|IDFOwG0>MXLTRW5ITVJ?
DELM{HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zHTGlEPTB;MT60N|Y2PyBizszNM3rQZ3NCVkeHUh?=
EW-16MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnZTWM2OD1zLkSzPVc{KCEQvF2=NV;sb45vW0GQR1XS
BPH-1NVi5VWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXmTWM2OD1zLkS0PFA2KCEQvF2=MVjTRW5ITVJ?
JARMnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXGzNmlPUUN3ME2xMlQ6OzZiIN88US=>NUnYSlVlW0GQR1XS
J-RT3-T3-5MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTFwNUG3NlIhKM7:TR?=MmfSV2FPT0WU
A375MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HPOGlEPTB;MT61NVc4OiBizszNMUnTRW5ITVJ?
SW954MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnwNIpKSzVyPUGuOVUxODdiIN88US=>MVrTRW5ITVJ?
Ca9-22NFf2dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnTTZpKSzVyPUGuOVYzPiBizszNMoPpV2FPT0WU
D-566MGMlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1eyXWlEPTB;MT61O|E2PSBizszNMVfTRW5ITVJ?
SCC-15M2fyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37KfGlEPTB;MT62NVgxPCBizszNNFLnTFhUSU6JRWK=
HD-MY-ZNF\hNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;Ib4FTUUN3ME2xMlY{PTh2IDFOwG0>NYjvNmU{W0GQR1XS
HT-1376NYGxNmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHje457UUN3ME2xMlY1OzZiIN88US=>MmXIV2FPT0WU
CAL-54M{LLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTFwNkW3NFkhKM7:TR?=NFP2dYtUSU6JRWK=
ONS-76MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTFwNke1OVEhKM7:TR?=NIfsOmRUSU6JRWK=
EFO-27NYnnOHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDITWM2OD1zLk[4PVIhKM7:TR?=NXnvN5pPW0GQR1XS
769-PM2mzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFwNkm1PVYhKM7:TR?=MlXZV2FPT0WU
MV-4-11MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFwNkm4OVYhKM7:TR?=MX\TRW5ITVJ?
NKM-1NVTQc4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\uRWlEPTB;MT63NVgxOiBizszNNHruRYRUSU6JRWK=
LOXIMVIM{fmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXhTWM2OD1zLke0OVk6KCEQvF2=NYn5cpBtW0GQR1XS
KYSE-140MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XkTmlEPTB;MT63OVY2PSBizszNNH6w[2tUSU6JRWK=
ES5NYmwWI9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXxVJlKSzVyPUGuPFY4PDdiIN88US=>NEC2OotUSU6JRWK=
BB65-RCCMoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzaTWM2OD1zLki5PFQ6KCEQvF2=M{H4THNCVkeHUh?=
HNMlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvNd2psUUN3ME2xMlg6QDd2IDFOwG0>MYrTRW5ITVJ?
A101DNIrBRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVq0OFJJUUN3ME2xMlk{PjJ6IDFOwG0>NX;idWZGW0GQR1XS
LoVoM3vWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2X4RWlEPTB;MT65O|Y4QSBizszNMkLoV2FPT0WU
NCI-H526Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\HTWM2OD1zLkm5N|I2KCEQvF2=NEHJc45USU6JRWK=
NCI-H1693Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTFwOUm4PFghKM7:TR?=NFv0VVZUSU6JRWK=
OVCAR-4NH6zdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJwMEC0N|UhKM7:TR?=M2TSNXNCVkeHUh?=
SK-HEP-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nB[GlEPTB;Mj6wNFc1PSBizszNMUHTRW5ITVJ?
C2BBe1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3LSplKSzVyPUKuNFM{PzJiIN88US=>MWXTRW5ITVJ?
MEL-JUSOMmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnSNm5SUUN3ME2yMlA1PDZ2IDFOwG0>MVPTRW5ITVJ?
MOLT-16NEPNbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjvXpFKSzVyPUKuNFcxPThiIN88US=>MW\TRW5ITVJ?
NBsusSRNWryUHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPzTWM2OD1{LkC5PFg6KCEQvF2=NHfINndUSU6JRWK=
TK10MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7W[2pKSzVyPUKuNVM1PThiIN88US=>M3\oOnNCVkeHUh?=
CAL-39NIXpN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS2cZRKSzVyPUKuNVQ1QCBizszNNIHmTlFUSU6JRWK=
NCI-H2030NIXQUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrwfY1KSzVyPUKuNVg6PzNiIN88US=>MV3TRW5ITVJ?
HCT-116NF;ufVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NImwV3pKSzVyPUKuNlI6QDRiIN88US=>MXvTRW5ITVJ?
HTC-C3NIWxSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXT6PXpKUUN3ME2yMlI3QDJ2IDFOwG0>NYTjfZRtW0GQR1XS
TYK-nuNX34Z212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDPTWM2OD1{LkOwPVA6KCEQvF2=MlLKV2FPT0WU
FADUNH7EdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJwM{KyPVYhKM7:TR?=MX\TRW5ITVJ?
A431NWrTd21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XLPGlEPTB;Mj6zO|AzPSBizszNNGnsfZZUSU6JRWK=
TE-11NYrrOYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjCTWM2OD1{LkO4NFE6KCEQvF2=M4OwcnNCVkeHUh?=
CAL-12TMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXsUXl4UUN3ME2yMlQxPDF5IDFOwG0>MXzTRW5ITVJ?
DBMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvYTWM2OD1{LkSyPFY6KCEQvF2=MkmzV2FPT0WU
L-363MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfvTWM2OD1{LkSzOVA4KCEQvF2=NFSzR4RUSU6JRWK=
MSTO-211HNGHifHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE[zXWFKSzVyPUKuOlY{QTFiIN88US=>NEf2[3pUSU6JRWK=
SK-UT-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIi5UJBKSzVyPUKuO|E1ODZiIN88US=>MmG3V2FPT0WU
RPMI-8226NEOxbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[4TWM2OD1{LkezNVY1KCEQvF2=MUTTRW5ITVJ?
SF295M1PWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;vcWlEPTB;Mj63OFMyKCEQvF2=NHrVR49USU6JRWK=
OS-RC-2Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjqOJJKSzVyPUKuO|Y3PzNiIN88US=>MXPTRW5ITVJ?
SK-MEL-24MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvLTWM2OD1{Lke4NlI1KCEQvF2=MV7TRW5ITVJ?
COR-L23MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJwN{m0OlQhKM7:TR?=M2XoZ3NCVkeHUh?=
MHH-PREB-1NGq4bJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1ThcWlEPTB;Mj64NFE3OSBizszNNUnzfo5OW0GQR1XS
SK-N-DZNX7UT3R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPJUI5OUUN3ME2yMlgyPjN6IDFOwG0>Mle0V2FPT0WU
OMC-1M{G0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\HTWM2OD1{Lki1NFA{KCEQvF2=NYPrVJgxW0GQR1XS
SK-MEL-2M{[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJwOEmyOFMhKM7:TR?=Mn:0V2FPT0WU
SASNFXaZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfjUGFSUUN3ME2yMlk6PDF3IDFOwG0>NH\hPY1USU6JRWK=
EPLC-272HMkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTNwMECyN|UhKM7:TR?=MUPTRW5ITVJ?
8505CMkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nEbWlEPTB;Mz6xNFMxOSBizszNMlvoV2FPT0WU
EW-11NGnOT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4O4WmlEPTB;Mz6xOFI4PyBizszNMUfTRW5ITVJ?
YKG-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nzR2lEPTB;Mz6xOFcxPiBizszNNHvOR5RUSU6JRWK=
EC-GI-10M37nTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXnfppKSzVyPUOuNVczPjNiIN88US=>NXjzS4lNW0GQR1XS
SK-LU-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorTTWM2OD1|LkG4OFE5KCEQvF2=NWDvPYlFW0GQR1XS
P30-OHKNWrGSmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LYSmlEPTB;Mz6yNFEyPyBizszNNIHHUWFUSU6JRWK=
T-24M4\J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXiTWM2OD1|LkKxPFE1KCEQvF2=NGLGXZJUSU6JRWK=
HSC-2NHHTTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TZUWlEPTB;Mz6yNlI{OiBizszNNX;hbpdOW0GQR1XS
SK-MES-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWixe3VxUUN3ME2zMlI1QDJ7IDFOwG0>MWrTRW5ITVJ?
SW48M3O4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\MS5VKSzVyPUOuNlU1QDZiIN88US=>NX7RfWd7W0GQR1XS
ME-180Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTNwMk[wOVEhKM7:TR?=NYLydlU5W0GQR1XS
NCI-H2009NXfNR|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTzTWM2OD1|LkK5NFEhKM7:TR?=M2fQdHNCVkeHUh?=
HL-60MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHZRYVKSzVyPUOuNlkyOyBizszNNUfW[Y1kW0GQR1XS
NCI-N87MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPJR4hLUUN3ME2zMlMxOTd{IDFOwG0>MUXTRW5ITVJ?
GMS-10NYixPIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHu[pNKSzVyPUOuN|QxQDZiIN88US=>NV:wUlBVW0GQR1XS
SCHNV64Wm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLS[WJHUUN3ME2zMlQxQDR2IDFOwG0>NWj3eJZRW0GQR1XS
C-33-ANYTQfHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTNwNEG0NlEhKM7:TR?=NWjZ[2lbW0GQR1XS
NCI-H1703MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH6TWM2OD1|LkSxPFEzKCEQvF2=M13pOXNCVkeHUh?=
A427MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLzTWM2OD1|LkS2NVI1KCEQvF2=MXTTRW5ITVJ?
MOLT-4Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjhTWM2OD1|LkS4NVk6KCEQvF2=M{D4e3NCVkeHUh?=
NCI-H1792MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHMVIRKSzVyPUOuOFk5ODJiIN88US=>M2ToWnNCVkeHUh?=
NCI-H1650MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmX1TWM2OD1|LkW3NlkhKM7:TR?=MWfTRW5ITVJ?
H-EMC-SSNXPh[mhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorSTWM2OD1|LkW4OVY6KCEQvF2=MnzTV2FPT0WU
SW982NFvRN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz0TVFKSzVyPUOuOVg5OjliIN88US=>NWPofmh3W0GQR1XS
DSH1NHfqSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYm3SWtOUUN3ME2zMlY1OTJ{IDFOwG0>NV;aUWNmW0GQR1XS
NOS-1NGTOUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[z[2tKSzVyPUOuOlQzPzZiIN88US=>MUTTRW5ITVJ?
BT-549MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIX3U4xKSzVyPUOuOlc5PTRiIN88US=>Mn7nV2FPT0WU
HuCCT1M13vVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTNwN{SxO|chKM7:TR?=M1SwR3NCVkeHUh?=
NCI-H1755NF;6SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnBW3hKSzVyPUOuPVY6PzFiIN88US=>NFH5NmVUSU6JRWK=
KYSE-450NEDUO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7jV|JKSzVyPUOuPVY6QTdiIN88US=>NXPnd41KW0GQR1XS
MIA-PaCa-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTNwOUeyPUAh|ryPMWHTRW5ITVJ?
U-266MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV:2[JJnUUN3ME2zMlk4PDhzIDFOwG0>MmXOV2FPT0WU
MewoMn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml2yTWM2OD12LkC2N|YyKCEQvF2=NIHHTHRUSU6JRWK=
KYSE-520Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnLbmhKSzVyPUSuNFk4QTliIN88US=>NVXQcG13W0GQR1XS
MN-60NVzCN4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzJTWM2OD12LkGwOVAyKCEQvF2=MkTqV2FPT0WU
Ramos-2G6-4C10M1vw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfIT5NKSzVyPUSuNVY4OzliIN88US=>NIr4dGhUSU6JRWK=
SK-MEL-1NFy0bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofwTWM2OD12LkG4Olk2KCEQvF2=NYXSU4V7W0GQR1XS
ABC-1NUX5d2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Pve2lEPTB;ND6yN|M{OyBizszNMnrJV2FPT0WU
CAKI-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrLPGg2UUN3ME20MlI1PTdzIDFOwG0>NYLIUXlJW0GQR1XS
HOSNYjIUlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX3TWM2OD12LkK5NVQyKCEQvF2=NX:xVZNCW0GQR1XS
SN12CNV3USXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTRwM{SyOFQhKM7:TR?=NXHVfJhNW0GQR1XS
NB13M3vLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\5TWM2OD12LkO3N|U2KCEQvF2=NV:4bFdvW0GQR1XS
M14MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqxVJEzUUN3ME20MlQ5Pzl{IDFOwG0>MW\TRW5ITVJ?
GP5dMojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4O1RWlEPTB;ND61NFEzKCEQvF2=M4HGO3NCVkeHUh?=
NCI-H720NH;6XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j0TGlEPTB;ND61N|YyOiBizszNM13vXXNCVkeHUh?=
D-423MGMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nZWmlEPTB;ND61N|kzPCBizszNMXfTRW5ITVJ?
ChaGo-K-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{m2OGlEPTB;ND61PVU2QSBizszNMWrTRW5ITVJ?
MEL-HONFe5S5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M172fGlEPTB;ND62NVI3OSBizszNMU\TRW5ITVJ?
MHH-ES-1MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfhdollUUN3ME20MlYzPDFzIDFOwG0>NXHxPZl5W0GQR1XS
KYSE-270NWH6dpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrhTWM2OD12Lk[1NVI3KCEQvF2=Ml3YV2FPT0WU
GI-ME-NMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDmbVVpUUN3ME20MlcyOjlzIDFOwG0>MoP3V2FPT0WU
HOP-92NY\DWlJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXO1XnlEUUN3ME20MlgyOzd7IDFOwG0>MU\TRW5ITVJ?
MKN1MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL4RXVRUUN3ME20Mlg{QTF2IDFOwG0>MkSzV2FPT0WU
ML-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTRwOEW2NlYhKM7:TR?=MnLxV2FPT0WU
RO82-W-1Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTRwOUK5PEAh|ryPNWfVVW5LW0GQR1XS
G-361NV;wSYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnzTWM2OD13LkCxNFA{KCEQvF2=NXXXRXFrW0GQR1XS
HC-1M2j5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTVwMEOyPVEhKM7:TR?=NGXqRVhUSU6JRWK=
EW-24NGDNcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnmNlhKSzVyPUWuNFQxOzhiIN88US=>MXnTRW5ITVJ?
HuP-T4NWjoTW45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTVwMUSzN|QhKM7:TR?=NEn6cFVUSU6JRWK=
8-MG-BAMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTVwM{SyPEAh|ryPM3zLeHNCVkeHUh?=
HGC-27MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u5[mlEPTB;NT6zO|Y5OiBizszNNEjJfZVUSU6JRWK=
TE-12MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnScpFzUUN3ME21MlQyPTh3IDFOwG0>NVvrOHE1W0GQR1XS
GT3TKBM1Xxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrGTFBKSzVyPUWuOFQzOTJiIN88US=>Mn32V2FPT0WU
DOHH-2MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3z1O2lEPTB;NT60OVk5PiBizszNNHntZlVUSU6JRWK=
Ca-SkiMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTVwNE[xNVUhKM7:TR?=NEDOdodUSU6JRWK=
A172M4TqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\Y[2xKSzVyPUWuOVQ6OjViIN88US=>MWLTRW5ITVJ?
EGI-1NHLPXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHVVFdKSzVyPUWuOVg6OzhiIN88US=>NGPUVVBUSU6JRWK=
MZ2-MELNWr6VIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHZTWM2OD13Lk[xOFg3KCEQvF2=MUfTRW5ITVJ?
SW1710M1PxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHJbIxKSzVyPUWuOlkxQTFiIN88US=>M3jBenNCVkeHUh?=
HT-144MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7TblFKSzVyPUWuO|I3QDViIN88US=>Ml6zV2FPT0WU
PA-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\sbWlEPTB;NT64NVg6OyBizszNMXvTRW5ITVJ?
HCC1937NYO0UI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLkT|dKUUN3ME21Mlg{QTJ7IDFOwG0>MoGxV2FPT0WU
SK-OV-3M4TUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;EUFRKSzVyPUWuPVEyOjFiIN88US=>M{T6N3NCVkeHUh?=
K5NYPUVlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWeybGc1UUN3ME22MlA2OTdiIN88US=>MXLTRW5ITVJ?
NMC-G1NETzemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjHTWM2OD14LkC3O|k4KCEQvF2=M1e4UHNCVkeHUh?=
MDA-MB-361M{HrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHCTY5CUUN3ME22MlA6OjZzIDFOwG0>NH7DcXVUSU6JRWK=
EKVXNVTVcZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUT1b4ROUUN3ME22MlE{PTBzIDFOwG0>MVfTRW5ITVJ?
ES7M3LVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXVVJV4UUN3ME22MlE3OTF3IDFOwG0>MVzTRW5ITVJ?
KS-1NUW3dHFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnpe2NKSzVyPU[uNVc6QTNiIN88US=>MVLTRW5ITVJ?
NCI-H661MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfyOoJrUUN3ME22MlE5ODhzIDFOwG0>NULiUHR5W0GQR1XS
ES8NVXxNIlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTZwMUiwPFIhKM7:TR?=M4nLe3NCVkeHUh?=
NCI-H23M{KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jiWWlEPTB;Nj6yNVgyPiBizszNMom1V2FPT0WU
T47DM{TkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTZwMk[0OVchKM7:TR?=M{foVHNCVkeHUh?=
A2780NXjGcIxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkj3TWM2OD14LkO3O|AyKCEQvF2=MWLTRW5ITVJ?
SCC-4M3TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml6xTWM2OD14LkSzOVYyKCEQvF2=Mor0V2FPT0WU
VA-ES-BJNUnoVXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTZwOUewOFMhKM7:TR?=M3fuN3NCVkeHUh?=
no-11M2frR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\ETW1rUUN3ME23MlE3PDFiIN88US=>Mnf2V2FPT0WU
KU-19-19M1LC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTdwMU[0O|YhKM7:TR?=NHWzOJJUSU6JRWK=
MKN45NIrCTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPveJFKSzVyPUeuNVg3QTliIN88US=>NILscWFUSU6JRWK=
SCC-25Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3z6cGlEPTB;Nz6yN|QyPCBizszNM4LlSHNCVkeHUh?=
ETK-1NHP1[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTdwMkW1NVQhKM7:TR?=MW\TRW5ITVJ?
COR-L88NWLxfm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LqemlEPTB;Nz6yPVMyQSBizszNNWrLSFJVW0GQR1XS
8305CM3j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlO5TWM2OD15LkOyOFkzKCEQvF2=MYjTRW5ITVJ?
Detroit562MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX2xcWwzUUN3ME23MlMzPTB4IDFOwG0>NX7JbmlOW0GQR1XS
SNU-449M2rqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTdwM{e2OVEhKM7:TR?=MmX2V2FPT0WU
A704NH3zOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fDc2lEPTB;Nz6zPFI4QCBizszNNUTlSoNbW0GQR1XS
D-502MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDRSHRzUUN3ME23MlM5PDd|IDFOwG0>MUfTRW5ITVJ?
NCI-H2228MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTdwNEG0OVghKM7:TR?=NUHPXppGW0GQR1XS
CHP-212Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[wbINUUUN3ME23MlUyQDl4IDFOwG0>NGP1T4lUSU6JRWK=
VMRC-RCZMl[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULQWYpJUUN3ME23MlU6ODZ4IDFOwG0>M3O3R3NCVkeHUh?=
RPMI-2650MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInJUJZKSzVyPUeuO|A{OTJiIN88US=>NFr6eFNUSU6JRWK=
HCC2218Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF:0WG9KSzVyPUeuO|IzPThiIN88US=>M171dnNCVkeHUh?=
GCTNYHhWWlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTdwOEKxO|IhKM7:TR?=NF2ydlBUSU6JRWK=
SW780M4\Td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoT2TWM2OD15Lkm5NFYhKM7:TR?=NHH6WGZUSU6JRWK=
KMOE-2NEHidpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\5bIlKSzVyPUiuNFQxPyBizszNNFqyO2dUSU6JRWK=
KYSE-180NIG3VJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYf3fFZFUUN3ME24MlA5PjR6IDFOwG0>MnHhV2FPT0WU
TE-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUD6PGlTUUN3ME24MlEyODV5IDFOwG0>M1vI[nNCVkeHUh?=
OAW-42MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRThwMkW0PVYhKM7:TR?=MWDTRW5ITVJ?
VM-CUB-1NX7NVIdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjUTWM2OD16LkK4N|Y1KCEQvF2=MWHTRW5ITVJ?
ECC10M1P0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRThwMkizPVchKM7:TR?=M3fKVnNCVkeHUh?=
SW1573MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\wTWM2OD16LkS0OFY2KCEQvF2=M2rIR3NCVkeHUh?=
NCI-H1299MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrzTWM2OD16LkW5O|c1KCEQvF2=M4PUWHNCVkeHUh?=
ALL-POM1\mZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnrc45KSzVyPUiuOlY2QTdiIN88US=>NVyybJNnW0GQR1XS
OVCAR-5NGLBfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRThwN{e2NlUhKM7:TR?=Ml;VV2FPT0WU
NCI-SNU-5NVTCSFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PNfGlEPTB;OD64N|AxOSBizszNMnvIV2FPT0WU
NCI-H2342M1vnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvDTWM2OD16LkizNVAyKCEQvF2=M37NcXNCVkeHUh?=
RPMI-7951NHK1R2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XBU2lEPTB;OD64OFE2PyBizszNMnrxV2FPT0WU
RCM-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPjWJJKSzVyPUmuNFgyPDViIN88US=>NGfrdYtUSU6JRWK=
DaoyNES0cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;X[JhKSzVyPUmuNVIxOjhiIN88US=>MUDTRW5ITVJ?
HCC1395MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTlwM{C4PVYhKM7:TR?=M2Xi[XNCVkeHUh?=
786-0MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfxTWM2OD17LkO2NFI3KCEQvF2=NFrnSVVUSU6JRWK=
GAMGNV\5R413T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\TTWM2OD17Lk[1OVM1KCEQvF2=MWPTRW5ITVJ?
HCC1954MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjvNVVKSzVyPUmuPFU5PTliIN88US=>MkTXV2FPT0WU
NCI-H1838NGm4T3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETFfZZKSzVyPUmuPVA{PzFiIN88US=>M{\6bHNCVkeHUh?=
SW620MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTlwOUWzOVchKM7:TR?=Mn61V2FPT0WU
NCI-H358MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFyLkSxPVchKM7:TR?=M2fzZ3NCVkeHUh?=
NCI-H1793MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTFyLkSyOFghKM7:TR?=NXG4PFdqW0GQR1XS
NCI-H1666NFu3R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TmUmlEPTB;MUCuOFM2PSBizszNNF7OXpRUSU6JRWK=
MZ7-melMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTFyLkS3OVMhKM7:TR?=NHnYSFdUSU6JRWK=
MDA-MB-175-VIINHznPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPsU3lKSzVyPUGwMlY{QTZiIN88US=>M1fI[3NCVkeHUh?=
COLO-829NXK2bI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEL1RVlKSzVyPUGwMlgxODRiIN88US=>NFPsXmNUSU6JRWK=
RVH-421MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHtdI9KSzVyPUGxMlE2OiBizszNMoHUV2FPT0WU
A549NGG2[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom3TWM2OD1zMT6yOFc5KCEQvF2=M1PzfHNCVkeHUh?=
DJM-1M1vZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\WNHNKSzVyPUGxMlM5OzNiIN88US=>MnmwV2FPT0WU
IST-MEL1M4HPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zGZmlEPTB;MUGuO|MyQSBizszNM3O1PXNCVkeHUh?=
BENNH;iZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojFTWM2OD1zMT63OFAzKCEQvF2=NVK1bnI4W0GQR1XS
KM12MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrzb4FVUUN3ME2xNU46ODlzIDFOwG0>Mlm1V2FPT0WU
HuO9MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTlToZXUUN3ME2xNk4xPjZ4IDFOwG0>MXHTRW5ITVJ?
U-2-OSM4\PeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmD6TWM2OD1zMj6wPFk{KCEQvF2=NYXQe3BlW0GQR1XS
RH-1M3rkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK3TWM2OD1zMj60OFczKCEQvF2=NXy2[WhFW0GQR1XS
NCI-H1048NHP5OHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmO1TWM2OD1zMj61OVA3KCEQvF2=NFL1TGZUSU6JRWK=
Mo-TMofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXwWpBiUUN3ME2xNk44OzB5IDFOwG0>MV\TRW5ITVJ?
KYSE-150MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TxdWlEPTB;MUKuO|Q2PSBizszNMmTVV2FPT0WU
A388MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlv2TWM2OD1zMj63O|E{KCEQvF2=MUHTRW5ITVJ?
NCI-SNU-1M13PUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPnelhKSzVyPUGyMlgxPDZiIN88US=>M2q4VHNCVkeHUh?=
HELNGj4TJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF{LkiyNVIhKM7:TR?=M4\1cXNCVkeHUh?=
UM-UC-3MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTF{Lki4O|QhKM7:TR?=NFr2VY1USU6JRWK=
TGBC24TKBM3Lpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7QTWM2OD1zMz6wNlY4KCEQvF2=M33MenNCVkeHUh?=
SW626MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF|LkK0PFUhKM7:TR?=NX7icoluW0GQR1XS
ES6MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NET6OFZKSzVyPUGzMlI2OTJiIN88US=>NYPLNoZFW0GQR1XS
NCI-H2029MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTF|LkixNFghKM7:TR?=MWjTRW5ITVJ?
RXF393NY\kO4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoW3TWM2OD1zMz65PVI4KCEQvF2=MmjlV2FPT0WU
HMV-IIMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\6TWM2OD1zND6wO|ghKM7:TR?=NFy3PWlUSU6JRWK=
EW-22MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLqTWM2OD1zND6xOVAzKCEQvF2=M3f3fHNCVkeHUh?=
AsPC-1MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37acmlEPTB;MUSuOVY1KCEQvF2=NEG3OZVUSU6JRWK=
COLO-678M3;Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7HTWM2OD1zND63NlcyKCEQvF2=M{fTXXNCVkeHUh?=
HCT-15MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorlTWM2OD1zND64PFU2KCEQvF2=NIm4PHpUSU6JRWK=
HCE-TM3LVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEe5UYVKSzVyPUG0Mlg5PzRiIN88US=>NGXUdZFUSU6JRWK=
SF539M3PLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzTTWM2OD1zNT6wOlQ{KCEQvF2=MV7TRW5ITVJ?
AU565M2\kRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXraSWdQUUN3ME2xOU4zODl4IDFOwG0>NW\tXIVjW0GQR1XS
JVM-2NGWyU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHlNHVKSzVyPUG1MlI3QDFiIN88US=>MXjTRW5ITVJ?
CaR-1NV\6dmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXJZXQzUUN3ME2xOU41PDF{IDFOwG0>NF70PHVUSU6JRWK=
23132-87MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3L3dmlEPTB;MUWuPFQ6PSBizszNMl3ZV2FPT0WU
A673NGLZO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2e2N2lEPTB;MUWuPVY{PiBizszNM3jJc3NCVkeHUh?=
KYSE-410M4jFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjOVHJKSzVyPUG2MlAzQSBizszNMX7TRW5ITVJ?
TE-9M{TxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13HbmlEPTB;MU[uNFYzKCEQvF2=Mn;jV2FPT0WU
LU-139MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HCVWlEPTB;MU[uNVgzOyBizszNMn7lV2FPT0WU
GCIYMlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLlTWM2OD1zNj6xPVE3KCEQvF2=M{jjN3NCVkeHUh?=
JEG-3MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PYSmlEPTB;MU[uNlUhKM7:TR?=NFGzSmNUSU6JRWK=
RT-112M1y4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M123PWlEPTB;MU[uOFE1OyBizszNM{SycXNCVkeHUh?=
COLO-680NMn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTF4LkWxNFghKM7:TR?=Ml3vV2FPT0WU
LU-134-ANHG4OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX62NY5DUUN3ME2xOk46QDl|IDFOwG0>NWfoVZhlW0GQR1XS
MFM-223NXziSGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrPR5dKSzVyPUG3MlE2OzViIN88US=>MmPpV2FPT0WU
SF126M1HMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3SVolEUUN3ME2xO{4yPzBzIDFOwG0>MlPWV2FPT0WU
NCI-H28NHzOeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF5LkKwOlYhKM7:TR?=MWLTRW5ITVJ?
BFTC-905MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf6RZZKSzVyPUG3MlQ5OzJiIN88US=>MkXPV2FPT0WU
SCC-9NXLvdndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3JTWM2OD1zNz62Nlg2KCEQvF2=MmjHV2FPT0WU
KNS-62M1PjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETLRnRKSzVyPUG3MlY3OjliIN88US=>MlvGV2FPT0WU
Hs-578-TNEnXXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\kWGlEPTB;MUeuPFE1QSBizszNNHX6ZpFUSU6JRWK=
D-336MGM4XwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDNXYtpUUN3ME2xO{45Ojl2IDFOwG0>NUPqSot7W0GQR1XS
NCI-H82NY\kcnhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXmTWM2OD1zOD6wNVg{KCEQvF2=MUTTRW5ITVJ?
EFM-19M{PZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHn6ZXpKSzVyPUG4MlA2PzdiIN88US=>MXXTRW5ITVJ?
TGBC11TKBM{jZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\pcow3UUN3ME2xPE4yODJzIDFOwG0>MnTJV2FPT0WU
HEC-1NHrET5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[zVWlEPTB;MUiuNlkyQCBizszNNGC5cZdUSU6JRWK=
HuP-T3NE\xUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF6LkW5NlkhKM7:TR?=MlO3V2FPT0WU
SF268NHTFUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXhTWM2OD1zOD62O|AzKCEQvF2=M13MZXNCVkeHUh?=
COLO-792M3nSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nUcWlEPTB;MUiuO|k6PyBizszNMnLNV2FPT0WU
HLEM2XFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTF6LkizN|EhKM7:TR?=M1rPSnNCVkeHUh?=
A204NUDoPWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\GTWM2OD1zOD65NVY1KCEQvF2=NELxfoJUSU6JRWK=
CAL-72NHzaO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvNe41KSzVyPUG5MlA5PzdiIN88US=>M3LLWnNCVkeHUh?=
U031MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPX[VhqUUN3ME2xPU41QTB7IDFOwG0>M4q5SXNCVkeHUh?=
FTC-133MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDRTWM2OD1zOT65N|A1KCEQvF2=NWHF[G1zW0GQR1XS
SK-MEL-28M3P0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJyLkO3OlEhKM7:TR?=MXjTRW5ITVJ?
KGNMkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkm0TWM2OD1{MD60Olk6KCEQvF2=NFG2XW1USU6JRWK=
HCC2998MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJzLkO5NlYhKM7:TR?=M3TLTXNCVkeHUh?=
GOTONFnvcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rofWlEPTB;MkGuOFg2KCEQvF2=Mnu2V2FPT0WU
AGSMlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPTOldKSzVyPUKxMlg1PTFiIN88US=>NWrGNFV1W0GQR1XS
EW-13M4PQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrvfmtpUUN3ME2yNk4yODJ{IDFOwG0>NYj3OJVqW0GQR1XS
P12-ICHIKAWAM33QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPJSmFKSzVyPUKyMlE3ODNiIN88US=>MlWxV2FPT0WU
NCI-H1395NV\rUFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfhbWFKSzVyPUKyMlI6ODdiIN88US=>NEfLepBUSU6JRWK=
A2058NUfaUFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\XPGlEPTB;MkKuOFM1KCEQvF2=Mm\GV2FPT0WU
SH-4MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TMU2lEPTB;MkKuO|A1PSBizszNNEPrTXZUSU6JRWK=
DoTc2-4510NGSwNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPzTWM2OD1{Mz62OFczKCEQvF2=MYHTRW5ITVJ?
MMAC-SFMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknrTWM2OD1{Mz62PVEyKCEQvF2=M133RXNCVkeHUh?=
NCI-H510AMl34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fTdWlEPTB;MkOuO|k{QSBizszNMXrTRW5ITVJ?
HDLM-2NFrHOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnMXFVKSzVyPUK0MlE1PiBizszNM1vMcnNCVkeHUh?=
KINGS-1M161[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Pv[mlEPTB;MkSuNlQzKCEQvF2=M{i4cnNCVkeHUh?=
NCI-H1648M17TNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmT1TWM2OD1{ND60NFI1KCEQvF2=MYrTRW5ITVJ?
HCC1187NH:yXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjPfW1KSzVyPUK1MlAzOzViIN88US=>NXjPfJhXW0GQR1XS
BALL-1M4XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPOdVBCUUN3ME2yOU4zODZ{IDFOwG0>NWTIWno2W0GQR1XS
SBC-1NHrDfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorETWM2OD1{NT6yPVk{KCEQvF2=NETnVXZUSU6JRWK=
BFTC-909NHroO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nGWWlEPTB;MkWuN|U2OSBizszNMoXXV2FPT0WU
MOLT-13MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3rTWM2OD1{NT62O|Q1KCEQvF2=M{ey[HNCVkeHUh?=
SW1990MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTJ3Lkm2OVUhKM7:TR?=NEX3Rm5USU6JRWK=
DK-MGMkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37ycWlEPTB;Mk[uNFQ1OyBizszNNIezeW9USU6JRWK=
TE-8Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTJ4LkC2OlghKM7:TR?=NUDUXYRwW0GQR1XS
BeckerMmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmixTWM2OD1{Nj6xOVc1KCEQvF2=NF7MbFVUSU6JRWK=
KYSE-70MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXQNJVKSzVyPUK2MlU{OTdiIN88US=>NF7DRXlUSU6JRWK=
MKN7NV[zTYFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3K3WWlEPTB;MkeuO|Q4QSBizszNM{DzfXNCVkeHUh?=
D-392MGNUnKe291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fvNmlEPTB;MkeuO|Y6PCBizszNNGnleolUSU6JRWK=
NH-12MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi1TWM2OD1{OD6xNlI6KCEQvF2=MU\TRW5ITVJ?
EW-18MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle1TWM2OD1{OD6yNlE5KCEQvF2=NVLEdHFpW0GQR1XS
LCLC-97TM1NHLjPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XkdmlEPTB;MkiuNlc3OiBizszNM{nEPHNCVkeHUh?=
NCI-H1770MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIm4UGxKSzVyPUK4MlM2PjZiIN88US=>NXO3c2FoW0GQR1XS
BT-20NY\HbGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjmeGdKSzVyPUK4MlM3QDViIN88US=>NI\ZeHJUSU6JRWK=
DBTRG-05MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\aUmlEPTB;MkiuOFg{QCBizszNMkTqV2FPT0WU
HPAF-IINFzqWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUm0dVNOUUN3ME2yPE44PzliIN88US=>M4XrPXNCVkeHUh?=
SW837M1HBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfmTWM2OD1{OT6zN|g2KCEQvF2=MYLTRW5ITVJ?
647-VNXTXO|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTJ7LkewNFMhKM7:TR?=MY\TRW5ITVJ?
J82MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7CTWM2OD1{OT64NFE{KCEQvF2=Mlj1V2FPT0WU
MC116NEO0d|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnG0TWM2OD1|MD6wO|M{KCEQvF2=MYXTRW5ITVJ?
NCI-H69MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TXZ2lEPTB;M{CuOlA6OyBizszNM1rGS3NCVkeHUh?=
NB6MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPH[JpKSzVyPUOxMlM3OjliIN88US=>NVfwVZpEW0GQR1XS
CAL-120M1j6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1u3R2lEPTB;M{KuOFMyPyBizszNM4iyeHNCVkeHUh?=
U-87-MGM4HXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoH5TWM2OD1|Mz6wNlUyKCEQvF2=MofhV2FPT0WU
NCI-H1304MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\6S2lEPTB;M{OuNFM2PCBizszNNVPSOGhoW0GQR1XS
YH-13NVy3fpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN|LkK1N|UhKM7:TR?=M3q0[nNCVkeHUh?=
RMG-INGT0cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTJT|NKSzVyPUOzMlQzQDViIN88US=>NEPZfYJUSU6JRWK=
LU-65MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XZd2lEPTB;M{SuNVQxQCBizszNNHPTRo5USU6JRWK=
GB-1NID2W3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rDcGlEPTB;M{WuNFczQSBizszNMUXTRW5ITVJ?
DU-4475MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTN3LkG1OVMhKM7:TR?=MnjZV2FPT0WU
SBC-5NHTlNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTN4LkW5NFIhKM7:TR?=Mk\BV2FPT0WU
OE33M1Owdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTPSIxwUUN3ME2zO{44PTd5IDFOwG0>NUnmXo0xW0GQR1XS
C8166NF;1RmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHCbpRpUUN3ME2zPE42OjZ5IDFOwG0>M3TlWXNCVkeHUh?=
COLO-684NVnIUVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTN6Lke0NlghKM7:TR?=NYjEPFBLW0GQR1XS
NCI-H1155Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnKzTWM2OD1|OT6wOFcyKCEQvF2=MXHTRW5ITVJ?
ATN-1MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;OTWM2OD1|OT63O|kzKCEQvF2=MXTTRW5ITVJ?
KARPAS-299MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XZUGlEPTB;M{muPFM6KCEQvF2=Ml65V2FPT0WU
KNS-81-FDNY\qeolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTRyLkO2NFQhKM7:TR?=NYmxbnhMW0GQR1XS
NCI-H1563NInHbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH4TWM2OD12MT61NFM6KCEQvF2=M{izU3NCVkeHUh?=
NB14Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvBUZBKSzVyPUSyMlczPjNiIN88US=>MlP6V2FPT0WU
COLO-800M2W2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\qc|VKSzVyPUSyMlg2OTdiIN88US=>MlToV2FPT0WU
MS-1MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTR|LkC0PFMhKM7:TR?=M4X1R3NCVkeHUh?=
OVCAR-8MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\T[nloUUN3ME20N{43QDB7IDFOwG0>M1\GXHNCVkeHUh?=
SK-PN-DWMoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFG3VmdKSzVyPUSzMlg4PzZiIN88US=>MnP2V2FPT0WU
G-402MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTR|LkmwNFYhKM7:TR?=NY\SRpV6W0GQR1XS
NCI-H2291NXS1dpZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nUcmlEPTB;NESuPFAyPyBizszNMWnTRW5ITVJ?
PC-3NH\ZRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX2wN455UUN3ME20OU45ODJ|IDFOwG0>NFrjSFlUSU6JRWK=
NCI-H1581MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4r0cmlEPTB;NEWuPVg5QSBizszNNYftVVBVW0GQR1XS
SW1116Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jZdGlEPTB;NEeuNFE5OiBizszNMlXIV2FPT0WU
ZR-75-30NGrldIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrWTWM2OD12Nz6wNlM6KCEQvF2=NWnk[VRXW0GQR1XS
OCI-AML2MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInHcGpKSzVyPUS3MlA6OThiIN88US=>MkfRV2FPT0WU
MDA-MB-231M{K2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4GwR2lEPTB;NEeuOlI1QSBizszNMljFV2FPT0WU
ES3M4nWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVP2WVJtUUN3ME20PE4{PTJ7IDFOwG0>MnLxV2FPT0WU
NCI-H630NVu0VGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTR7LkG3OFIhKM7:TR?=MlnGV2FPT0WU
OE19NXfGO|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PkXWlEPTB;NEmuNlkxOiBizszNMn3pV2FPT0WU
NCI-H1573NVrsOVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\2ZZpKSzVyPUS5MlY5PjFiIN88US=>MV7TRW5ITVJ?
EW-1MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:5eGlEPTB;NEmuPVA5PCBizszNNUL1bmp5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02501330 Active, not recruiting Chronic Myelogenous Leukemia Pfizer July 2015 --
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --
NCT02445742 Recruiting Chronic Myeloblastic Leukaemia PETHEMA Foundation May 2015 Phase 2

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation (3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Product Use Citation (11)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us